RANK ligand and TNF-α mediate acid-induced bone calcium efflux in vitro

American Journal of Physiology - Renal Physiology

Volumn 289, Issue 5 58-5, 2005, Pages

  Frick, Kevin K ^a   LaPlante, Kelly ^a   Bushinsky, David A ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Bone resorption; Chronic metabolic acidosis; Osteoblastic collagen synthesis; Tumor necrosis factor

Indexed keywords

CALCIUM ION; CYTOKINE; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CALVARIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLIC ACIDOSIS; MOUSE; NEWBORN; NONHUMAN; ORGAN CULTURE; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL;

EID: 26844512510     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00420.2004     Document Type: Article

References (64)

1. Adams ND, Gray RW, and Lemann J Jr. The calciuria of increased fixed acid production in humans: evidence against a role for parathyroid hormone and 1,25(OH)2-vitamin D. Calcif Tissue Int 28: 233-238, 1979.
2. Alexander EH, Bento JL, Hughes FM Jr, Marriott I, Hudson MC, and Bost KL. Staphylococcus aureus and Salmonella enterica serovar Dublin induce tumor necrosis factor-related apoptosis-inducing ligand expression by normal mouse and human osteoblasts. Infect Immun 69: 1581-1586, 2001.
3. Aubin JE and Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 11: 905-913, 2000.
4. Azuma Y, Kaji K, Katogi R, Takeshita S, and Kudo A. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J Biol Chem 275: 4858-4864, 2000.
5. Barzel US. The skeleton as an ion exchange system: implications for the role of acid-base imbalance in the genesis of osteoporosis. J Bone Miner Res 10: 1431-1436, 1995.
6. Brandstrom H, Bjorkman T, and Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun 280: 831-835, 2001.
7. Burgess T, Qian YX, Kaufman S, Ring BD, Van G, Capparelli C, Kelley MJ, Hsu H, Boyle WJ, Dunstan CR, Hu S, and Lacey DL. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145: 527-538, 1999.
8. Bushinsky DA. Net proton influx into bone during metabolic, but not respiratory, acidosis. Am J Physiol Renal Fluid Electrolyte Physiol 254: F306-F310, 1988.
9. Bushinsky DA. Net calcium efflux from live bone during chronic metabolic, but not respiratory, acidosis. Am J Physiol Renal Fluid Electrolyte Physiol 256: F836-F842, 1989.
10. Bushinsky DA. Metabolic acidosis. In: The Principles and Practice of Nephrology, edited by Jacobson HR, Striker GE, and Klahr S. St. Louis, MO: Mosby, 1995, p. 924-932.
11. Bushinsky DA. Stimulated osteoclastic and suppressed osteoblastic activity in metabolic but not respiratory acidosis. Am J Physiol Cell Physiol 268: C80-C88, 1995.
12. Bushinsky DA. The contribution of acidosis to renal osteodystrophy. Kidney Int 47: 1816-1832, 1995.
13. Bushinsky DA. Metabolic alkalosis decreases bone calcium efflux by suppressing osteoclasts and stimulating osteoblasts. Am J Physiol Renal Fluid Electrolyte Physiol 271: F216-F222, 1996.
14. Bushinsky DA, Goldring JM, and Coe FL. Cellular contribution to pH-mediated calcium flux in neonatal mouse calvariae. Am J Physiol Renal Fluid Electrolyte Physiol 248: F785-F789, 1985.
15. Bushinsky DA and Krieger NS. Regulation of bone formation and dissolution. In: Kidney Stones: Medical and Surgical Management, edited by Coe F, Favus M, Pak C, Parks J, and Preminger G. New York: Raven, 1996, p. 239-258.
16. Bushinsky DA, Krieger NS, Geisser DI, Grossman EB, and Coe FL. Effects of pH on bone calcium and proton fluxes in vitro. Am J Physiol Renal Fluid Electrolyte Physiol 245: F204-F209, 1983.
17. Bushinsky DA and Nilsson EL. Additive effects of acidosis and parathyroid hormone on mouse osteoblastic and osteoclastic function. Am J Physiol Cell Physiol 269: C1364-C1370, 1995.
18. 2 levels and calcium release. Am J Physiol Renal Physiol 281: F1058-F1066, 2001.
19. Chambers TJ. Regulation of the differentiation and function of osteoclasts. J Pathol 192: 4-13, 2000.
20. Coe FL and Bushinsky DA. Pathophysiology of hypercalciuria. Am J Physiol Renal Fluid Electrolyte Physiol 247: F1-F13, 1984.
21. Colucci S, Brunetti G, Rizzi R, Zonno A, Mori G, Colaianni G, Del Prete D, Faccio R, Liso A, Capalbo S, Liso V, Zallone A, and Grano M. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 104: 3722-3730, 2004.
22. Flores-Figueroa E, Gutierrez-Espindola G, Montesinos JJ, Arana-Trejo RM, and Mayani H. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 26: 677-686, 2002.
23. Frick KK and Bushinsky DA. Chronic metabolic acidosis reversibly inhibits extracellular matrix gene expression in mouse osteoblasts. Am J Physiol Renal Physiol 275: F840-F847, 1998.
24. Frick KK and Bushinsky DA. In vitro metabolic and respiratory acidosis selectively inhibit osteoblastic matrix gene expression. Am J Physiol Renal Physiol 277: F750-F755, 1999.
25. Frick KK and Bushinsky DA. Metabolic acidosis stimulates RANK ligand RNA expression in bone through a cyclooxygenase dependent mechanism. J Bone Miner Res 18: 1317-1325, 2003.
26. Frick KK, Jiang L, and Bushinsky DA. Acute metabolic acidosis inhibits the induction of osteoblastic egr-1 and type 1 collagen. Am J Physiol Cell Physiol 272: C1450-C1456, 1997.
27. Fuller K, Wong B, Fox S, Choi Y, and Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188: 997-1001, 1998.
28. Gilbert L, He X, Farmer P, Rubin J, Drissi H, van Wijnen AJ, Lian JB, Stein GS, and Nanes MS. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-α. J Biol Chem 277: 2695-2701, 2002.
29. Goater JJ, O'Keefe RJ, Rosier RN, Puzas JE, and Schwartz EM. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. J Orthop Res 20: 169-173, 2002.
30. Green J and Kleeman CR. Role of bone in regulation of systemic acid-base balance. Kidney Int 39: 9-26, 1991.
31. Haddad JJ. Cytokines and related receptor-mediated signaling pathways. Biochem Biophys Res Commun 297: 700-713, 2002.
32. Haddad JJ. Pharmaco-redox regulation of cytokine-related pathways: from receptor signaling to pharmacogenomics. Free Radic Biol Med 33: 907-926, 2002.
33. Hofbauer LC and Heufelder AE. Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology. J Mol Med 79: 243-253, 2001.
34. Horowitz MC, Xi Y, Wilson K, and Kacena MA. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 12: 9-18, 2001.
35. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, and Boyle WJ. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 3540-3545, 1999.
36. Katagiri T and Takahashi N. Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 8: 147-159, 2002.
37. Kerstetter JE, O'Brian KO, and Insogna KL. Dietary protein, calcium metabolism, and skeletal homeostasis revisited. Am J Clin Nutr 78: 584S-592S, 2003.
38. Kobayashi K, Takahashi H, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, and Suda T. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191: 275-286, 2000.
39. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, and Peninger JM. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323, 1999.
40. Krieger NS, Frick KK, and Bushinsky DA. Mechanism of acid-induced bone resorption. Curr Opin Nephrol Hypertens 13: 423-436, 2004.
41. Krieger NS, Parker WR, Alexander KM, and Bushinsky DA. Prostaglandins regulate acid-induced cell-mediated bone resorption. Am J Physiol Renal Physiol 279: F1077-F1082, 2000.
42. Krieger NS, Sessler NE, and Bushinsky DA. Acidosis inhibits osteoblastic and stimulates osteoclastic activity in vitro. Am J Physiol Renal Fluid Electrolyte Physiol 262: F442-F448, 1992.
43. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan C, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, and Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176, 1998.
44. Lemann J Jr, Adams ND, and Gray RW. Urinary calcium excretion in human beings. N Engl J Med 301: 535-541, 1979.
45. Lemann J Jr, Bushinsky DA, and Hamm LL. Bone buffering of acid and base in humans. Am J Physiol Renal Physiol 285: F811-F832, 2003.
46. Lemann J Jr, Litzow JR, and Lennon EJ. The effects of chronic acid loads in normal man: further evidence for the participation of bone mineral in the defense against chronic metabolic acidosis. J Clin Invest 45: 1608-1614, 1966.
47. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Jaun SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, and Boyle WJ. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97: 1566-1571, 2000.
48. Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, and Xing L. RANK signaling is not required for TNFα-mediated increase in CD11 (hi) osteoclast precursors but is essential for mature osteoclast formation in TNFα-mediated inflammatory arthritis. J Bone Miner Res 19: 207-213, 2004.
49. 2 signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/ receptor activator of nuclear factor-κB (RANK) ligand/RANK system. Endocrinology 146: 1991-1998, 2005.
50. 2 in fetal rat osteoblasts: role of protein kinase A signaling pathway. J Bone Miner Res 13: 1092-1100, 1998.
51. Millet I and Vignery A. The neuropeptide calcitonin gene-related peptide inhibits TNF-α but poorly induces IL-6 production by fetal rat osteoblasts. Cytokine 9: 999-1007, 1997.
52. Miyamoto N, Higuchi Y, Mori K, Ito M, Tsurudome M, Nishio M, Yamada H, Sudo A, Kato K, Uchida A, and Ito Y. Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. Int Immunopharmacol 2: 25-38, 2002.
53. Onishi M, Nosaka T, and Kitamura T. Cytokine receptors: structures and signal transduction. Int Rev Immunol 16: 617-634, 1998.
54. Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, and Zannettino AC. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-α converting enzyme (TACE). J Bone Miner Res 19: 147-154, 2004.
55. 2 and cyclic adenosine 3′,5′-monophosphoric acid and their relationship to bone resorption in neonatal mouse calvaria cultures. Bone Miner 11: 295-304, 1990.
56. Sabokbar A, Kudo O, and Athanasou NA. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. J Orthop Res 21: 73-80, 2003.
57. Sakai H, Kobayashi Y, Sakai E, Shibata M, and Kato Y. Cell adhesion is a prerequisite for osteoclast survival. Biochem Biophys Res Commun 270: 550-556, 2000.
58. 2 synthesized de novo. Cytokine 18: 133-139, 2002.
59. 2 is crucially involved in lipopolysaccharide-induced osteoclast formation. J Immunol 172: 2504-2510, 2004.
60. Suda T, Kobayashi K, Jimi E, Udagawa N, and Takahashi N. The molecular basis of osteoclast differentiation and activation. Novartis Found Symp 232: 235-247, 2001.
61. Widdowson EM and Dickerson JWT. Chemical composition of the body. In: Mineral Metabolism, edited by Comar CL and Bronner F. New York: Academic, 1964, p. 1-247.
62. Zauli G, Rimondi E, Nicolin V, Melloni E, Celeghini C, and Secchiero P. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 104: 2044-2050, 2004.
63. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee AB, and Abu-Amer Y. Tumor necrosis factor-α (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 276: 563-568, 2001.
64. Zou W, Hakim I, Tschoep K, Endres S, and Bar-Shavit Z. Tumor necrosis factor-α mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem 83: 70-83, 2001.